Impairment of the intestinal epithelial barrier, accompanied by local and systemic inflammation, underlies numerous human pathologies, including inflammatory bowel diseases, celiac disease, sepsis, as well as severe acute malnutrition. Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG (LGG®) have been shown in preclinical studies to strengthen the gut epithelial barrier and attenuate inflammation. This study aimed to compare the ability of four commercial strains of B. infantis, LGG, and their combination to mitigate inflammation-mediated epithelial damage using an in vitro immunocompetent intestinal model. A microfluidic mid-throughput platform OrganoPlate® was used to co-culture intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells (PBMCs). Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide (LPS), and probiotic-conditioned media were applied to the apical side of Caco-2 cells to assess effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics significantly protected the epithelium by modulating tight junction protein expression and promoting transcription of homeostatic cytokines, resulting in a “leak-tight” phenotype. These findings indicate that metabolites produced by B. infantis and/or LGG can protect the intestinal epithelium in vitro, warranting further in vivo studies to evaluate the translational relevance of this effect.
Severe acute malnutrition is associated with enteropathy manifested as disruption of epithelial tight junctions and increased gut permeability, associated with intestinal and systemic inflammation. Bifidobacterium longum subsp. infantis (B. infantis) and Lacticaseibacillus rhamnosus GG (LGG ®, Chr. Hansen A/S) have been shown to strengthen the gut epithelial barrier and to reduce inflammation in preclinical studies. The aim of this study was to compare the ability of four commercial strains of B.infantis, LGG and their combination to mitigate inflammation-mediated epithelial damage using an in-vitro immunocompetent model of the intestine. A microfluidic mid-throughput device OrganoPlate® (Mimetas B.V.) was employed to enable the co-culturing of intestinal epithelial cells (Caco-2) with peripheral blood mononuclear cells. Epithelial damage was induced by stimulating PBMCs with lipopolysaccharide and probiotic conditioned media were added to the apical side of the Caco-2 to test the effects on barrier integrity, cytokine secretion, and gene transcription. All tested probiotics demonstrated significant protection of the epithelium via modulation of tight-junction proteins and homeostatic cytokines gene transcription promoting a “leak-tight” phenotype. These findings demonstrate that B. infantis and/or LGG may have the potential to protect the intestinal epithelium and thus could contribute to alleviating intestinal enteropathy in malnourished children.
The intestinal microbiota and immune system are separated by an epithelial layer, whose barrier function is crucial for the healthy state of the host, while its impairment, usually associated with inflammation, leads to a variety of pathologies in humans. Different probiotics targeting the preservation of epithelial barrier homeostasis are thus currently being developed. Their selection and validation are a complex process involving in-vitro and in-vivo models. While the former lacks the complexity of the physiological system, the latter often fails to reflect the effect in humans. We used the commercial microfluidic high-throughput device OrganoPlate to set up a Gut-on-Chip model comprising human epithelial and peripheral blood mononuclear cells (PBMC). As a proof-of-concept, we co-cultured several intestinal anaerobic bacteria species in direct contact with the epithelial monolayer for two days to investigate their impact on epithelial barrier integrity and immune response upon induction of inflammation. We demonstrate here that Bacteroides thetaiotaomicron protects the epithelial barrier and dampens CCL2 secretion provoked by LPS-stimulated PBMC. Recapitulating the key features of intestinal inflammation, we suggest that the current Gut-on-Chip model enables an easy-to-use screen of next-generation probiotics and live biotherapeutics with homeostatic and immunomodulatory properties.
The intestinal microbiota plays a crucial role in maintaining epithelial barrier integrity, while its impairment and the resulting inflammation contribute to numerous human pathologies. To preserve intestinal homeostasis, various probiotics are being developed; however, their selection and validation require accessible yet physiologically relevant models. We recently established a high-throughput Gut-on-Chip model comprising human epithelial (Caco-2) cells and peripheral blood mononuclear cells (PBMCs), demonstrating epithelial barrier disruption and pro-inflammatory cytokine secretion upon inflammation induction. The present study aimed to evaluate the feasibility of co-culturing anaerobic members of the human intestinal microbiota within this model and to assess their effects on inflammation-induced epithelial damage. We successfully co-cultured five intestinal anaerobic bacterial species in direct contact with the epithelial monolayer for two days. As proof of concept, we demonstrate that live Bacteroides thetaiotaomicron and its supernatant preserve epithelial barrier integrity and attenuate CCL2 secretion by Caco-2 cells. In contrast, Clostridium scindens did not prevent epithelial damage but suppressed CCL20 secretion, revealing a promising target for future studies. By recapitulating some of the key aspects of intestinal inflammation, we suggest that the current Gut-on-Chip model has potential as an easy-to-use platform for screening next-generation probiotics and live biotherapeutics with homeostatic and immunomodulatory properties.
5 February 2026 in Sensors and Actuators B: Chemical